<?xml version='1.0' encoding='utf-8'?>
<document id="23200184"><sentence text="Clinical impact of drug-drug interaction between aspirin and prednisolone at a cancer center."><entity charOffset="49-56" id="DDI-PubMed.23200184.s1.e0" text="aspirin" /><entity charOffset="61-73" id="DDI-PubMed.23200184.s1.e1" text="prednisolone" /><pair ddi="false" e1="DDI-PubMed.23200184.s1.e0" e2="DDI-PubMed.23200184.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23200184.s1.e0" e2="DDI-PubMed.23200184.s1.e1" /></sentence><sentence text="Adverse gastrointestinal (GI) events are complications in aspirin and prednisolone cotherapy"><entity charOffset="58-65" id="DDI-PubMed.23200184.s2.e0" text="aspirin" /><entity charOffset="70-82" id="DDI-PubMed.23200184.s2.e1" text="prednisolone" /><pair ddi="false" e1="DDI-PubMed.23200184.s2.e0" e2="DDI-PubMed.23200184.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23200184.s2.e0" e2="DDI-PubMed.23200184.s2.e1" /></sentence><sentence text=" The prevalence of adverse GI events would be expected to be increased with cotherapy due to the overlapping toxicities of the 2 drugs" /><sentence text=" However, there is a dearth of literature investigating how often this interaction causes clinically important adverse GI events" /><sentence text="" /><sentence text="This retrospective study aimed to determine the prevalence of adverse GI events associated with the coadministration of aspirin and prednisolone"><entity charOffset="120-127" id="DDI-PubMed.23200184.s6.e0" text="aspirin" /><entity charOffset="132-144" id="DDI-PubMed.23200184.s6.e1" text="prednisolone" /><pair ddi="false" e1="DDI-PubMed.23200184.s6.e0" e2="DDI-PubMed.23200184.s6.e0" /><pair ddi="false" e1="DDI-PubMed.23200184.s6.e0" e2="DDI-PubMed.23200184.s6.e1" /></sentence><sentence text=" The use of gastroprotectant agents was also studied" /><sentence text="" /><sentence text="The medical records of patients with cancer prescribed aspirin and prednisolone therapy between January 2007 and June 2011 were analyzed"><entity charOffset="55-62" id="DDI-PubMed.23200184.s9.e0" text="aspirin" /><entity charOffset="67-79" id="DDI-PubMed.23200184.s9.e1" text="prednisolone" /><pair ddi="false" e1="DDI-PubMed.23200184.s9.e0" e2="DDI-PubMed.23200184.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23200184.s9.e0" e2="DDI-PubMed.23200184.s9.e1" /></sentence><sentence text=" The duration of aspirin-prednisolone overlap, prevalence of adverse GI events, and details on the concurrent use of other medications were evaluated"><entity charOffset="17-24" id="DDI-PubMed.23200184.s10.e0" text="aspirin" /><entity charOffset="25-37" id="DDI-PubMed.23200184.s10.e1" text="prednisolone" /><pair ddi="false" e1="DDI-PubMed.23200184.s10.e0" e2="DDI-PubMed.23200184.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23200184.s10.e0" e2="DDI-PubMed.23200184.s10.e1" /></sentence><sentence text="" /><sentence text="The study included data from 142 patients (male, 64" /><sentence text="8%; mean [SD] age, 67" /><sentence text="4 [11" /><sentence text="0] years)" /><sentence text=" A total of 78" /><sentence text="9% of the patients were on some form of gastroprotectant, the most common class of which was proton pump inhibitors" /><sentence text=" The prevalence of adverse GI events was 4" /><sentence text="2% (6 patients)" /><sentence text=" Four patients had presented with GI symptoms (abdominal pain, diarrhea, dysphagia, and vomiting); 3 patients had signs of GI injury (duodenal ulcers, iron deficiency anemia, and a Mallory-Weiss tear)"><entity charOffset="151-155" id="DDI-PubMed.23200184.s20.e0" text="iron" /></sentence><sentence text=" The Naranjo algorithm classified 5 patients experienced possible adverse drug reactions (ADRs), and 1 as a probable ADR" /><sentence text="" /><sentence text="Our study found that the prevalence of adverse GI events was low and managed to establish a weak association between the occurrence of events and the coadministration of aspirin and prednisolone"><entity charOffset="170-177" id="DDI-PubMed.23200184.s23.e0" text="aspirin" /><entity charOffset="182-194" id="DDI-PubMed.23200184.s23.e1" text="prednisolone" /><pair ddi="false" e1="DDI-PubMed.23200184.s23.e0" e2="DDI-PubMed.23200184.s23.e0" /><pair ddi="false" e1="DDI-PubMed.23200184.s23.e0" e2="DDI-PubMed.23200184.s23.e1" /></sentence><sentence text=" This finding, together with the concurrent prescription of gastroprotectants, suggests that the clinical impact of the aspirin and prednisolone DDI is minimal"><entity charOffset="120-127" id="DDI-PubMed.23200184.s24.e0" text="aspirin" /><entity charOffset="132-148" id="DDI-PubMed.23200184.s24.e1" text="prednisolone DDI" /><pair ddi="false" e1="DDI-PubMed.23200184.s24.e0" e2="DDI-PubMed.23200184.s24.e0" /><pair ddi="false" e1="DDI-PubMed.23200184.s24.e0" e2="DDI-PubMed.23200184.s24.e1" /></sentence><sentence text="" /></document>